Equitable access to high-cost pharmaceuticals /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Babar, Zaheer-ud-din (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London, United Kingdom : Academic Press, an imprint of Elsevier, 2018.
Temas:
Drugs > Prices.
Drugs > Prices > Law and legislation.
Pharmacy > methods
Economics, Pharmaceutical
Pharmacy > organization & administration
M�edicaments > Prix.
Pharmaco�economie.
BUSINESS & ECONOMICS > Industries > General.
Drugs > Prices
Drugs > Prices > Law and legislation
Internet Resources.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover; Title Page; Copyright Page; Dedication; Contents; Contributors; Foreword; Chapter 1
  • Access to High Cost Medicines: An Overview; Abbreviations; 1.1
  • Defining HCMs; 1.2
  • Value of HCMs; 1.3
  • Accessibility of HCMs; 1.4
  • Approaches for promoting access to HCMs; 1.5
  • Conclusion; Note; References; Chapter 2
  • Health Technology Assessment; 2.1
  • Introduction; 2.2
  • What is health technology assessment (hta)?; 2.3
  • Technologies; 2.4
  • Principles underpinning HTA processes; 2.5
  • Evidence-based decision-making for the subsidy of health technologies.
  • 2.5.1
  • Criteria Used to Inform Subsidy Decisions2.5.2
  • Threshold for Value for Money; 2.5.3
  • Considering Multiple Criteria in Decision-making; 2.6
  • Who�a#x80;#x99;s involved? Stakeholders at the table; 2.7
  • Future directions in health technology assessment for high cost medicines; 2.8
  • Summary; References; Chapter 3
  • High-Cost Medicines in England; 3.1
  • Introduction; 3.2
  • Background; 3.2.1
  • Policy in History; 3.2.2
  • National Arrangements; 3.2.3
  • NICE Guidance; 3.2.4
  • The Carter Review; 3.3
  • High-cost drugs; 3.3.1
  • Specialised Services; 3.3.2
  • Cancer Drugs Fund.
  • 3.3.3
  • Hospital Medicines Optimisation3.4
  • The way ahead; 3.5
  • Conclusions; References; Further Reading; Chapter 4
  • Managed Entry Agreements and High Cost Medicines (European Perspective); 4.1
  • Rationale for mea; 4.2
  • Definition and taxonomy of mea; 4.3
  • Diffusion of mea in europe; 4.4
  • Impact evaluation and future perspectives; References; Chapter 5
  • Setting a Public Health Agenda to Support Access to High-Cost Medicines; 5.1
  • Introduction; 5.2
  • The emerging significance of the impact of high-cost medicines; 5.3
  • European cooperation; 5.4
  • G7 and G20.
  • 5.5
  • The un high-level panel on access to medicines5.6
  • Who fair pricing forum; 5.6.1
  • What Is a Fair Price? And How Is Such a Fair Price to Be Achieved?; 5.6.2
  • Towards the Fair Pricing System; 5.7
  • Conclusion; Acknowledgements; References; Chapter 6
  • Human Rights and Intellectual Property for Universal Access to New Essential Medicines; 6.1
  • Introduction; 6.2
  • Access to essential medicines in the era of intellectual property and human rights; 6.2.1
  • The WTO TRIPS Agreement�a#x80;#x94;Globalising Intellectual Property Rules; 6.2.2
  • HIV and the Drive for Change in Intellectual Property.
  • 6.2.3
  • The Emergence of Access to Essential Medicines in the Right to Health6.2.4
  • Doha Declaration on TRIPS and Public Health; 6.2.5
  • Patents and New Essential Medicines; 6.3
  • Human rights obligations of governments; 6.3.1
  • Maximum Available Resources; 6.3.2
  • Efficient Use of Government Resources; 6.3.3
  • Prioritising Medicines for Reimbursement; 6.3.4
  • Use of Price Control Mechanisms and TRIPs Flexibilities; 6.4
  • Protecting access to medicines in international fora; 6.4.1
  • Human Rights Obligations of the Pharmaceutical Industry; 6.5
  • Conclusion; References; Further reading.
  • Chapter 7
  • Access to High Price Medicines in Portugal.

Ejemplares similares